Michael Ulz
Stock Analyst at Morgan Stanley
(4.70)
# 156
Out of 5,152 analysts
105
Total ratings
62.71%
Success rate
37.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michael Ulz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Overweight | $50 → $47 | $14.73 | +219.08% | 4 | Mar 3, 2026 | |
| AARD Aardvark Therapeutics | Downgrades: Equal-Weight | $29 → $7 | $5.70 | +22.81% | 2 | Mar 2, 2026 | |
| GUTS Fractyl Health | Downgrades: Equal-Weight | $8 → $2 | $0.49 | +312.20% | 3 | Jan 30, 2026 | |
| MIRM Mirum Pharmaceuticals | Maintains: Overweight | $95 → $123 | $90.51 | +35.90% | 6 | Jan 30, 2026 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Equal-Weight | $495 → $408 | $323.58 | +26.09% | 13 | Jan 30, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Equal-Weight | $48 → $81 | $64.57 | +25.45% | 7 | Jan 7, 2026 | |
| KYTX Kyverna Therapeutics | Maintains: Overweight | $20 → $25 | $8.44 | +196.21% | 3 | Dec 4, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $90 → $94 | $75.35 | +24.75% | 8 | Oct 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Overweight | $98 → $102 | $30.40 | +235.53% | 4 | Oct 23, 2025 | |
| KPTI Karyopharm Therapeutics | Maintains: Outperform | $25 → $21 | $8.90 | +135.96% | 8 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $25 | $5.21 | +379.85% | 12 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $3.20 | +587.50% | 6 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $20 | $4.31 | +364.04% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $7 | $1.37 | +410.95% | 8 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $27 | $13.30 | +103.01% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $30 → $20 | $0.93 | +2,060.53% | 3 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $4.69 | +859.49% | 1 | Feb 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $10 | $0.54 | +1,765.67% | 3 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $3 | $4.52 | -33.55% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $18 → $30 | $9.13 | +228.59% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $80 | $21.62 | +270.03% | 3 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $15 | $14.34 | +4.64% | 3 | Jul 12, 2017 |
Dyne Therapeutics
Mar 3, 2026
Maintains: Overweight
Price Target: $50 → $47
Current: $14.73
Upside: +219.08%
Aardvark Therapeutics
Mar 2, 2026
Downgrades: Equal-Weight
Price Target: $29 → $7
Current: $5.70
Upside: +22.81%
Fractyl Health
Jan 30, 2026
Downgrades: Equal-Weight
Price Target: $8 → $2
Current: $0.49
Upside: +312.20%
Mirum Pharmaceuticals
Jan 30, 2026
Maintains: Overweight
Price Target: $95 → $123
Current: $90.51
Upside: +35.90%
Alnylam Pharmaceuticals
Jan 30, 2026
Maintains: Equal-Weight
Price Target: $495 → $408
Current: $323.58
Upside: +26.09%
Arrowhead Pharmaceuticals
Jan 7, 2026
Maintains: Equal-Weight
Price Target: $48 → $81
Current: $64.57
Upside: +25.45%
Kyverna Therapeutics
Dec 4, 2025
Maintains: Overweight
Price Target: $20 → $25
Current: $8.44
Upside: +196.21%
Ionis Pharmaceuticals
Oct 30, 2025
Maintains: Overweight
Price Target: $90 → $94
Current: $75.35
Upside: +24.75%
Viking Therapeutics
Oct 23, 2025
Maintains: Overweight
Price Target: $98 → $102
Current: $30.40
Upside: +235.53%
Karyopharm Therapeutics
Oct 9, 2025
Maintains: Outperform
Price Target: $25 → $21
Current: $8.90
Upside: +135.96%
May 9, 2025
Maintains: Overweight
Price Target: $45 → $25
Current: $5.21
Upside: +379.85%
Apr 1, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $3.20
Upside: +587.50%
Feb 28, 2025
Maintains: Outperform
Price Target: $24 → $20
Current: $4.31
Upside: +364.04%
Feb 27, 2024
Maintains: Equal-Weight
Price Target: $3 → $7
Current: $1.37
Upside: +410.95%
Aug 16, 2023
Maintains: Outperform
Price Target: $15 → $27
Current: $13.30
Upside: +103.01%
Mar 24, 2023
Maintains: Equal-Weight
Price Target: $30 → $20
Current: $0.93
Upside: +2,060.53%
Feb 1, 2023
Initiates: Overweight
Price Target: $45
Current: $4.69
Upside: +859.49%
Jan 27, 2023
Maintains: Overweight
Price Target: $20 → $10
Current: $0.54
Upside: +1,765.67%
Jan 27, 2023
Downgrades: Equal-Weight
Price Target: $3
Current: $4.52
Upside: -33.55%
Jan 27, 2023
Upgrades: Equal-Weight
Price Target: $18 → $30
Current: $9.13
Upside: +228.59%
Nov 3, 2017
Maintains: Outperform
Price Target: $85 → $80
Current: $21.62
Upside: +270.03%
Jul 12, 2017
Maintains: Outperform
Price Target: $12 → $15
Current: $14.34
Upside: +4.64%